Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3): a Prospective, Randomized, Open-label, Blinded-endpoint, Multi-center Trial

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The effect of head position as a nonpharmacological therapy on acute ischemic stroke (AIS) remains inconclusive. Recent HOPES2 (Head dOwn-Position for acutE moderate ischemic Stroke with large artery atherosclerosis) suggest the safety, feasibility, and potential benefit of the head-down position (HDP) in acute ischemic stroke. The current study aims to investigate the efficacy and safety of HDP in acute moderate ischemic stroke patients with large artery atherosclerosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years old

• Acute ischemic stroke confirmed by NCCT or MRI;

• Moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours of onset, or progressing from mild (NIHSS ≤ 5) to moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours, requiring ≥ 4 point increase in NIHSS score although the onset time is beyond 24 hours;

• Probable large artery atherosclerosis etiology based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria (responsible artery stenosis ≥ 50% or occlusion);

• Anterior circulation stroke (internal carotid artery, M1 or M2 of middle cerebral artery);

• First stroke onset or past stroke without obvious neurological deficit (mRS≤2);

• Signed informed consent.

Locations
Other Locations
China
Department of Neurology, General Hospital of Northern Theater Command
RECRUITING
Shenyang
Time Frame
Start Date: 2024-01-10
Estimated Completion Date: 2026-10-30
Participants
Target number of participants: 600
Treatments
Experimental: Head-down position
head-down position as an adjunct to guideline-based treatment
Other: control
guideline-based treatment
Related Therapeutic Areas
Sponsors
Leads: General Hospital of Shenyang Military Region

This content was sourced from clinicaltrials.gov